|
業務類別
|
Biotechnology |
|
業務概覽
|
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide. |
| 公司地址
| 910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878 |
| 電話號碼
| +1 240 654-1450 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.altimmune.com |
| 員工數量
| 59 |
| Mr. Jerome B. Durso |
Chairman of the Board, President and Chief Executive Officer |
-- |
01/12/2025 |
| Mr. Gregory L. Weaver |
Chief Financial Officer and Principal Accounting Officer |
-- |
15/08/2025 |
| Dr. Christophe Arbet-Engels, M.D.,PhD |
Chief Medical Officer |
-- |
03/10/2025 |
| Dr. M. Scot Roberts, PhD |
Chief Scientific Officer |
美元 468.56K |
15/08/2025 |
| Mr. Raymond M. Jordt, M.B.A. |
Chief Business Officer |
-- |
15/08/2025 |
|
|
| Mr. Jerome B. Durso |
Chairman of the Board, President and Chief Executive Officer |
01/12/2025 |
| Dr. Mitchel Sayare,PhD |
Independent Director |
15/08/2025 |
| Mr. John M. Gill |
Independent Director |
15/08/2025 |
| Mr. Wayne Pisano |
Independent Director |
15/08/2025 |
| Dr. Diane K. Jorkasky, M.D. |
Independent Director |
15/08/2025 |
| Ms. Teri L. Lawver |
Director |
25/02/2025 |
| Mr. Philip L. Hodges |
Independent Director |
15/08/2025 |
| Dr. Klaus O. Schafer, M.D.,M.P.H. |
Independent Director |
15/08/2025 |
| Dr. Catherine Angell Sohn, Pharm.D. |
Independent Director |
15/08/2025 |
|
|
|
|
